Gritstone Description
Our immunotherapy approach starts with our understanding of antigens. We also know which neoantigens will be present on cells by Human leukocyte antigen molecules. This will allow us to identify the ones that will be transcribed and translated. Gritstone EDGETM is our machine-learning-based platform that enables us to accomplish this. It is difficult to develop cancer immunotherapies that include tumor specific neoantigens. Tumors can have hundreds of mutations. However, only a small number of these mutations result in true tumor-specific antigens. We used EDGE's new integrated neural network architecture to train it with millions of data points from hundreds tumor and normal tissue samples taken from patients of different ancestries.